Preparation, in-vitro and in-vivo characterization of transdermal patch containing glibenclamide and atenolol: a combinational approach

• Published in: Pakistan journal of pharmaceutical sciences Vol. 24; no. 2; pp. 155 - 163
• Main Authors: Anitha, Posina, Ramkanth, Sundarapandiyan, Saleem, Mohamed T S, Umasankari, Kommireddy, Reddy, Boddu Praveen, Chetty, Madhusudhana
• Format: Journal Article
• Language: English
• Published: Pakistan Pakistan Journal of Pharmaceutical Sciences 01.04.2011
• Subjects: Administration, Cutaneous; Animals; Atenolol; Atenolol - administration & dosage; Atenolol - chemistry; Atenolol - pharmacokinetics; Diabetes; Dosage and administration; Drug therapy; Glibenclamide; Glyburide - administration & dosage; Glyburide - chemistry; Glyburide - pharmacokinetics; Goats; Hypertension; In Vitro Techniques; Male; Rabbits; Rats; Rats, Wistar; Pakistan
• ISSN: 1011-601X

A novel aspiration in treatment of chronic disease like diabetes associated with other non communicable disease risk factors, such as hypertension is to provide greater therapeutic effect, overcome the side effects by complex therapeutic regimen and to improve patient compliance upon administering combinational transdermal delivery of Glibenclamide (G) and Atenolol (A) which have not been tested literally. Hence, the present study was designed to develop a transdermal patch containing Glibenclamide and Atenolol using blends of different polymeric combinations such as Hydroxy propyl methyl cellulose (HPMC), Poly vinyl pyrolidone (PVP) and Carbopol (CP). The patches were subjected to physicochemical parameters, in-vitro and in-vivo drug release and in-vitro skin permeation studies. Good results were obtained in all the evaluated parameters. The drug release of all formulation follows zero order kinetics by diffusion mechanism of non fickian diffusion type. In-vitro transdermal permeation studies by using rat & goat skin and finally in-vivo studies by using rabbits were carried out for the optimized formulation (GA4 HPMC 1%, PVP 0.5%, CP 0.5%). The developed transdermal delivery system containing Glibenclamide & Atenolol might be a milestone in the combinational therapy of diabetes and hypertension.